Friday, December 1, 2017

Best Post of August 2017: Choroid plexus carcinoma in an infant

The next in our "Best of the Month" Series is from August 1, 2017:

Some papillary architecture is maintained

Monday, November 27, 2017

Best Post of June 2017: Remarkable en bloc dissection of human central and peripheral nervous system accomplished at University of Colorado

The next in our "Best of the Month" Series is from June 7, 2017:

Shannon Curran, MS with her dissection
Shannon Curran, a graduate student in the Modern Human Anatomy Program at the University of Colorado Anschutz Medical Campus, recently completed an en bloc dissection of the central nervous system along with an extensive portion of the peripheral nervous system from a human cadaver donor.  "It's pretty amazing," said Assistant Professor Maureen Stabio "There are only a handful of these prosections in the world ... We are so lucky to have such talented and ambitious students on our campus."

Curran, who is known among students and faculty as a preternaturally efficient prosector, completed the dissection in under 100 hours. Further detailed work is planned on the specimen, including dissection of the extraocular muscles away from the eyeballs while maintaining their connection to the brain. Discussion is underway about loaning the specimen to the Denver Museum of Nature and Science for community health education.

CNS en bloc dissection with extensive portion of PNS



Connection to the eyeballs is maintained, with plans to dissect away extraocular muscles



Detail showing maintained connection with digital nerves of the left hand

Monday, November 6, 2017

Choroidal hemangioma in a patient with Stuge-Weber Syndrome

Sclera is at bottom of picture; retinal pigment epithelium is at top right. Between them is choroid with cavernous hemangioma

Wednesday, November 1, 2017

Guest Post from Sandro Santagata, MD, PhD: Papillary Craniopharyngioma Trial

I am pleased to present a guest post from Dr. Sandro Santagata of Brigham and Women’s Hospital/Dana Farber Cancer Center, who writes:



Our group of collaborators has recently opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas that is sponsored by the Alliance for Clinical Trials in Oncology.

The eligibility criteria are listed here: https://clinicaltrials.gov/ct2/show/NCT03224767

The trial is based on work published in these two papers:


I am happy to answer any questions that our colleagues may have about this trial.  ssantagata@bics.bwh.harvard.edu

Tuesday, October 31, 2017

Neuropathology Blog is Ten Years Old Today


Ten years ago today, I put up the first post to neuropathology blog. At the time, I didn't intend for anyone to actually read any of this stuff. I thought the blog would be a convenient way of taking searchable notes on various neuropathology topics I came across.  Ten years (and 703 posts!) later, the blog has thus far had more than 850,000 page views. I'd like to particularly thank two early supporters: Drs. John Donahue and Mark Cohen. Thanks to both of you for your encouragement early on. And thanks to all the readers and contributors who have participated in making this blog a success over the last decade. Here's to ten more years!

Drs. John Donahue (left) and Mark Cohen

Friday, October 27, 2017

Neuropathologist Hannes Vogel featured in New York Times for examining brain of Las Vegas mass murderer

Prominent neuropathologist Hannes Vogel of Stanford University was featured in the New York Times yesterday as he is examining the brain of Stephen Paddock, who killed 58 concertgoers in Las Vegas this month in a rampage without any clear motive. Here's the link to the NYT article.


Hannes Vogel, MD

Wednesday, October 11, 2017

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Following up on the last post, Dr. Mike Lawlor sent me this in an email:

"Audentes Therapeutics officially announced the dosing of the first patient for the X-linked myotubular myopathy treatment trial that we’ve been working on over the past few years.  We’ve been very involved in the translation from dogs to humans, and will be doing the human pathology work for the trial.  Here’s a link to that press release."

Monday, October 2, 2017

Lawlor featured in video about his work in myotubular myopathy

Michael Lawlor, MD, PhD

Medical College of Wisconsin is highlighting the work of our colleague Dr. Michael Lawlor in the area of gene therapy for myotubular myopathy. Check out this wonderful 4-minute video!